Targeted Delivery of Triptolide Alleviates Diabetic Nephropathy via Inactivation of JAK2-STAT1 Signaling

HUANG Rongshuang, LI Xinrui, GUO Fan, LI Yanping, MA Liang, FU Ping

Abstract


Objective 

Inflammation and fibrosis are key features of diabetic nephropathy (DN). Triptolide (TP) exhibits anti-inflammatory and anti-fibrotic properties, though its mechanisms of action in DN remain unclear. CREKA (Cys-Arg-Glu-Lys-Ala) is a pentapeptide that specifically binds to fibronectin (FN), and the CREKA-modified liposome (CREKA-Lip) represents a novel FN-targeted drug delivery system. This study aimed to investigate the role of TP in diabetic db/db mice and determine whether encapsulation within CREKA-Lip enhances therapeutic efficacy while reducing the multi-organ toxicity of TP.

Methods 

Eight-week-old diabetic db/db mice received tail vein injections twice weekly with vehicle, free TP, or CREKA-Lip/TP for 10 weeks. Urine and serum parameters were measured, and kidney, heart, liver, and testis tissues were collected for pathological evaluation. Protein-protein interaction networks were constructed using Cytoscape and its plug-ins to identify core targets and elucidate the therapeutic mechanism of TP against DN. Inflammatory, fibrotic, apoptotic, and lipid metabolism markers were evaluated in the kidneys of diabetic mice with DN and in high glucose-treated mouse mesangial cells and podocytes using qPCR, Western blot, immunohistochemistry, and immunofluorescence assays.

Results 

TP administration reduced fasting blood glucose levels and glomerular mesangial expansion in diabetic mice. TP significantly suppressed renal inflammation, fibrosis, and apoptosis while enhancing lipid metabolism. Integration of network pharmacology, molecular docking, and transcriptomics revealed that TP ameliorated DN by inhibiting the JAK2-STAT1 signaling pathway. In vitro, TP inhibited high glucose-induced phosphorylation of JAK2 and STAT1, reduced collagen production in mesangial cells, decreased apoptosis, and improved lipid metabolism in podocytes. Moreover, CREKA-Lip/TP exhibited superior efficacy compared with free TP, with a more sustained reduction in urine albumin-to-creatinine ratio and greater inhibition of mesangial expansion. Notably, CREKA-Lip/TP treatment did not induce systemic toxicity.

Conclusion 

TP improves renal inflammation, fibrosis, apoptosis, and lipid homeostasis, thereby ameliorating DN by inhibiting JAK2-STAT1 activation. Targeted delivery of TP via FN-binding CREKA-Lip enhances therapeutic efficacy while minimizing multi-organ toxicity.

 

Keywords: Diabetic nephropathy, Triptolide, STAT1, Polypeptide-liposome, Toxicity

 

Full Text:

PDF


References


KALANTAR-ZADEH K, JAFAR T H, NITSCH D, et al. Chronic kidney disease. Lancet, 2021, 398: 786-802. doi: 10.1016/S0140-6736(21)00519-5.

UBARA Y, SAWA N, YAMANOUCHI M, et al. New interpretation of diabetic nephropathy or diabetic kidney disease from kidney biopsy: review article. Clin Exp Nephrol, 2025, 29: 875-887. doi: 10.1007/s10157-025-02661-4.

RAYEGO-MATEOS S, RODRIGUES-DIEZ R R, FERNANDEZ-FERNANDEZ B, et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int, 2023, 103: 282-296. doi: 10.1016/j. kint.2022.10.030.

BRENNAN E, KANTHARIDIS P, COOPER M E, et al. Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function. Nat Rev Nephrol, 2021, 17: 725-739. doi: 10.1038/s41581-021-00454-y.

SONG J, HE G N, DAI L. A comprehensive review on celastrol, triptolide and triptonide: Insights on their pharmacological activity, toxicity, combination therapy, new dosage form and novel drug delivery routes. Biomed Pharmacother, 2023, 162: 114705. doi: 10.1016/j.biopha.2023. 114705.

LIANG D, MAI H, RUAN F, et al. The efficacy of triptolide in preventing diabetic kidney diseases: a systematic review and Meta-analysis. Front Pharmacol, 2021, 12: 728758. doi: 10.3389/fphar.2021.728758.

ZHOU Z, QUTAISH M, HAN Z, et al. MRI detection of breast cancer micrometastases with a fibronectin-targeting contrast agent. Nat Commun, 2015, 6: 7984. doi: 10.1038/ncomms8984.

OKUR A C, ERKOC P, KIZILEL S. Targeting cancer cells via tumor-homing peptide CREKA functional PEG nanoparticles. Colloids Surf B Biointerfaces, 2016, 147: 191-200. doi: 10.1016/j.colsurfb.2016.08.005.

WANG C, WANG X, ZHONG T, et al. The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo. Int J Nanomedicine, 2015, 10: 2229-2248. doi: 10.2147/IJN.S79840.

JIANG K, SONG X, YANG L, et al. Enhanced antitumor and anti-metastasis efficacy against aggressive breast cancer with a fibronectin-targeting liposomal doxorubicin. J Control Release, 2018, 271: 21-30. doi: 10.1016/j.jconrel.2017.12.026.

HU X, LI J, FU M, et al. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther, 2021, 6: 402. doi: 10.1038/s41392-021-00791-1.

HE H, WANG H, CHEN X, et al. Treatment for type 2 diabetes and diabetic nephropathy by targeting Smad3 signaling. Int J Biol Sci, 2024, 20: 200-217. doi: 10.7150/ijbs.87820.

HUANG F, WANG Q, GUO F, et al. FoxO1-mediated inhibition of STAT1 alleviates tubulointerstitial fibrosis and tubule apoptosis in diabetic kidney disease. EBioMedicine, 2019, 48: 491-504. doi: 10.1016/j. ebiom.2019.09.002.

XING Y W, LIU K Z. Azithromycin inhibited oxidative stress and apoptosis of high glucose-induced podocytes by inhibiting STAT1 pathway. Drug Dev Res, 2021, 82: 990-998. doi: 10.1002/ddr.21801.

LI R, LI Y, ZHANG J, et al. Targeted delivery of celastrol to renal interstitial myofibroblasts using fibronectin-binding liposomes attenuates renal fibrosis and reduces systemic toxicity. J Control Release, 2020, 320: 32-44. doi: 10.1016/j.jconrel.2020.01.017.

BANES-BERCELI A K, SHAW S, MA G, et al. Effect of simvastatin on high glucose- and angiotensin Ⅱ-induced activation of the JAK/STAT pathway in mesangial cells. Am J Physiol Ren Physiol, 2006, 291: F116-21. doi: 10.1152/ajprenal.00502.2005.

HUANG J S, LEE Y H, CHUANG L Y, et al. Cinnamaldehyde and nitric oxide attenuate advanced glycation end products-induced the JAK/STAT signaling in human renal tubular cells. J Cell Biochem, 2015, 116: 1028-1038. doi: 10.1002/jcb.25058.

YOU W, LIU S, LI J, et al. GADD45A regulates subcutaneous fat deposition and lipid metabolism by interacting with Stat1. BMC Biol, 2023, 21: 212. doi: 10.1186/s12915-023-01713-z.

LI Y, HU Q, LI C, et al. PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease. J Clin Invest, 2019, 129: 1129-1151. doi: 10.1172/JCI121987.

REN L, WAN R, CHEN Z, et al. Triptolide alleviates podocyte epithelial-mesenchymal transition via kindlin-2 and EMT-related TGF-β/Smad signaling pathway in diabetic kidney disease. Appl Biochem Biotechnol, 2022, 194: 1000-1012. doi: 10.1007/s12010-021-03661-2.

WANG H Q, WU H X, SHI W Q, et al. Triptolide attenuates renal slit diagram to tight junction transition in diabetic kidney disease by regulating Nrf2-ferroptosis pathway. Am J Chin Med, 2024, 52: 2161-2185. doi: 10.1142/S0192415X24500836.


Refbacks

  • There are currently no refbacks.